Summary BW12C (5-[2-formyl-3-hydroxypenoxyl] 
Considerable effort has recently been invested in the exploration of possible techniques for the manipulation of tissue oxygenation in cancer therapy. While increased oxygenation would be expected to improve response to radiotherapy in circumstances where its efficacy is limited by the presence of hypoxic cells, decreased oxygenation also has important potential applications. These lie primarily in two fields: in the activation or potentiation of bioreductive agents and in the potentiation of hyperthermic damage. Bioreductive agents are specifically designed to be activated or dramatically potentiated in a reducing environment, such as is thought to exist in many solid tumours (Sartorelli, 1988) . Mitomycin C (Kennedy, 1987) , RSU 1069 (Stratford et al., 1986) and SR 4233 (Zeman et al., 1986) are currently the leading drugs of different subclasses of this type of agent and development in this area is very active. Hyperthermic damage has long been known to be enhanced by hypoxia and consequent pH changes in vitro (Overgaard & Bichel, 1977; Gerweck et al., 1979) , and recent in vivo data show that acute hypoxia associated with reduced blood flow can potentiate thermal damage in murine tumours (Horsman et al., 1989; Honess et al., 1991a) .
BW12C (5-[2-formyl-3-hydroxyphenoxy] pentanoic acid) is
a drug which binds to and stabilises oxyhaemoglobin, thus causing a left shift in the oxygen saturation curve. This has been demonstrated in vitro for human blood (Beddell et al., 1984) and in vivo in human volunteers (Fitzharris et al., 1985) , sickle cell patients (Keidan et al., 1986) cancer patients (Ramsay et al., 1991) , pigs (van den Aardweg et al., 1991) and mice Honess et al., 1991b) . For any partial pressure of oxygen the left-shifted haemoglobin releases less oxygen to the tissues and in consequence hypoxia is induced. This reduction in oxygen release will take place in all tissues, but a tumour-selective element lies in the fact that the oxygen tension in the tumour is thought to be typically lower than elsewhere, hence a further reduction may be sufficient to generate a reducing environment appropriate for bioreduction or thermosensitisation. BW12C has previously been shown to protect both murine tumours , Honess et al., 1991b and human tumour xenografts (Cole & Robbins, 1989 ) from radiation, in a manner consistent with an increase in hypoxic fraction. In the Lewis lung tumour , KHT tumour (Adams et al., 1989) and MAWI xenograft (Cole & Robbins, 1989) , all grown subcutaneously, the effect was compatible with the induction of complete hypoxia, but in RIF-1 intramuscular tumours the radioprotection was more modest (Honess et al., 1991b) . Preliminary blood flow studies suggested that the increase in hypoxic fraction might. be at least partially due to a reduction in tumour perfusion (Honess et al., 1989) . The thermosensitivity of the intramuscular RIF-I tumour was shown not to be affected by the drug (Honess et al., 1989) , but the hypoxic fraction in this tumour is very low and it seemed possible that the degree of hypoxia achieved was inadequate to enhance thermosensitivity. In the light of these observations the aims of the present study were:
(a) to measure the change in radiobiological hypoxic fraction brought about by BW12C in two murine tumours, each grown in two separate sites (b) to investigate the effect of BW12C on the thermosensitivity of the KHT tumour which is reported to have a higher inherent hypoxic fraction than that of the RIF-1 tumour (Moulder & Rockwell, 1984) and (c) to conduct a more detailed study of the effect of BW12C on the relative tissue perfusion of one tumour in two sites and in a range of normal tissues.
Materials and methods
Animals and tumour models Female C3H/Km mice 10-16 weeks old were used for this study. The RIF-1 RIF-1 tumours at 10-11 days after inoculation in the leg and 14-15 days after inoculation in the flank and for KHT tumours at 7-8 days after inoculation in the leg and 10-11 days after inoculation in the flank. 
Irradiation
This was carried out using a 250 kV X-ray machine (Pantak, UK) at a dose rate of 67.4 cGy min '. Unanaesthetised mice were placed in a subdivided, ventilated perspex box for treatment. BW12C or PBS was given 30 min before the start of irradiation and mice were put in the box immediately after injection to allow acclimatisation to the box before treatment. The time interval of 30 min between administration of BW12C and the start of irradiation was selected since previous work with the RIF-l tumour has shown that the radioprotective effect of BW12C is maximal in this system with this time interval (Honess et al., 1991b) . Anoxic conditions were achieved by killing the mice by enclosing the box in another container and gassing with nitrogen for 15 min before and during irradiation. These experiments were carried out on mice bearing a single tumour in either the leg or the flank.
Hyperthermia
This was administered to unanaesthetised mice as previously described (Honess et al., 1991a) . Briefly, the heating system used is a combined computer-controlled radiofrequency and waterbath device which allows uniform heating of a tumourbearing leg with temperature control to within ± 0.1°C of target temperature (Walton et al., 1989) . This apparatus is designed specifically for the treatment of intramuscular tumours in the leg and is not appropriate for the treatment of flank tumours. BW12C was given 30 min before the start of heating which was for 30 min. Unheated animals were sham-heated by restraint in the customised jigs, with insertion of dummy rectal and tumour thermocouples, for 30 min.
Assay of tumour response to radiotherapy or hyperthermia Tumour response to radiotherapy was measured by clonogenic cell survival as previously described for RIF-1 (Honess & Bleehen, 1982) and for KHT (Honess et Calculation of hypoxic fraction The hypoxic fractions of RIF-I and KHT tumours in both locations were calculated by the paired survival curve method (Moulder & Rockwell, 1984) i.e. measuring the separation of the survival curves on the hypoxic tail of the response curve for air-breathing animals. In cases where the survival curve for tumours in air-breathing animals did not become parallel to the curve for hypoxic tumours, an estimate of hypoxic fraction was made by calculating the separation of the curves at the highest radiation dose used. This gives a minimum value for hypoxic fraction (Moulder & Rockwell, 1984 Sapirstein (1959) and used as previously described (Honess & Bleehen, 1991 The tissues of interest included the RIF-l tumour, growing intramuscularly in the leg and intradermally in the flank, and the 'upstream' tissues for these tumour sites, namely muscle and skin. In order to avoid contamination of normal tissue by tumour in a manner compatible with rapid excision of all tissues (i.e. within 90-120 s of killing the animal), muscle and skin samples were taken from the contralateral leg and flank. In these experiments mice carried a tumour in each site, to enable comparison of the effects of BW12C on RTP of tumours in different sites in the same animals. The other tissues of interest were kidney, lung, liver and spleen. The lung and kidney differ from the other organs assayed in that they are relatively high flow tissues in comparison with the others; control extraction values are around 8-9% and 20-25% injected 86Rb per gram respectively, in contrast with values range from 1-3% injected 86Rb per gram for the other tissues, including tumour. The high flow rates reflect the 'service' capacity of these organs, and only a small and unmeasured proportion of the flow comprises their own nutritive flow. Nonetheless, variable changes in extraction rates are seen with different vasoactive agents, and such changes probably reflect to a certain extent changes in cardiac output. Since cardiac output cannot yet be measured in unanaesthetised mice, these changes are valuable indicators of the actions of a drug.
Measurement of renalfunction
The effect of BW12C on renal function was assayed by monitoring clearance of intravenously injected 51CrEDTA as previously described (Honess & Bleehen, 1991) . Five mice were used per time-point and plasma EDTA concentration was measured at 5, 10, 30 and 60min after injection.
Data analysis This was carried out on a Macintosh SE/30 computer. Means and standard errors of these means were calculated using the Statview program; unpaired, two-tailed t-tests were carried out where appropriate using the Statworks program. Regression analysis of radiation dose-response curves and EDTA plasma clearance curves, to measure slopes and intercepts and their associated errors, was also carried out using the Statworks program.
Results
Effect of BW12C on tumour radiation response Radiation dose response curves for RIF-1 and KHT tumours grown in the leg or in the flank are presented in Figure 1 for animals receiving PBS or 70 mg kg-' BW12C 30 min before the start of radiation. BW12C had no effect on the survival of unirradiated cells. Data are also presented for tumours in animals killed by nitrogen asphyxiation, showing the radiosensitivity of anoxic cells. The parameters describing these dose-response curves are presented in Table I . BW12C (P= 0.008 ) and also at 2 h the flank RTP of 78% is lower than the RTP for leg tumours (P = 0.002) The effects of 70 mg kg-' BW12C on the RTP of other normal tissues are shown in the lower two panels. Kidney, spleen and lung and show qualitatively the same response, although with marked differences in magnitude of change.
There is a significant increase in RTP from 30 min after treatment, with a peak typically at 1 h and the increase still significant 2 h after treatment, but there is a return to normal values by 6 h. The largest increase was seen in spleen, where RTP at 1 h was almost doubled to 173% of control, while peak RTP for kidney was 157% of control at 30 min and for lung was 128% of control at 1 h. All these increases are highly significant (at 1 h and 2 h after treatment P = 10-4 for all three tissues; at 30 min after treatment P = 10-4 for kidney, P = 0.004 for spleen and P = 10-3 for lung). In contrast in liver there was no significant increase in RTP in the first hour after treatment, but at 2 h and 6 h there were reductions to 85% (P = 0.02) and 79% (P = 0.01) respectively. Data to show the dose-response of these relative perfusion effects are presented in Figure 3 . This experiment was carried out with flank tumours because the effect of BW12C on RTP in flank tumours is larger than in leg tumours (see above). Further experiments (not shown) have indicated that the effect of BW12C in reducing tumour RTP is greater in larger tumours, therefore the dose-response was investigated in larger tumours of 450-550 mm3 in size. The data show (top panel) that the threshold dose for reduction in tumour RTP lies between 55 and 70 mg kg-'. RTP was reduced to 58% of control by 70mg kg-' (P = 10-4 compared with control), a somewhat larger reduction than was seen in the 250-450 mm3 tumours (Figure 2) , as expected. In kidney, the increase in RTP was evident at both 55 and 70 mg kg-', with RTP values of 143% and 142% respectively (P<0.005) but the increase at 40mgkg-' to 121% of control was not significant (P = 0.115). In spleen, all doses tested resulted in a significant increase in RTP; values were 172%, 168% and 158% at 40, 55 and 70 mg kg-' respectively. No change from control was observed in liver at the time chosen for this assay, which is in agreement with the findings presented in Figure 2 . In lung however, as in kidney, there were significant increases in RTP following 55 and 70 mg kg', with RTP values of 129% and 136% respectively (P = 0.007 and P = 0.003 respectively) but at 40 mg kg-' there was no change from control. These normal tissue data show good agreement with the data presented in Figure 2 for the same BW12C dose and time of assay. The data as a whole indicate that perturbations in normal tissue perfusion occur at lower BW12C doses than do reductions in tumour perfusion in these animals.
RIF-1 tumours both intramuscularly in the leg and intradermally in the flank is very similar to that originally reported by Brown et al. (1980) 
Effect of BW12C on renalfunction
The effect of 70 mg kg-' BW12C on renal function was assayed by the ability of the mouse to clear 5"CrEDTA from the plasma. BW12C was given either together with EDTA or 30 min before EDTA. The parameters of the clearance curves measured are presented in Table II and show that when BW12C was given simultaneously with EDTA the rate of clearance was slightly reduced by a factor (± 2 s.e.) of 1.26 ± 0.27. When EDTA was given 30 min after BW12C, at which time the perturbation of kidney RTP was maximal, there was no change in clearance rate. There was no change in intercept of the curve for either administration schedule. A further experiment was carried out investigating the effect of BW12C on the clearance of "25I iodohippurate given 30 min after BW12C (data not shown) and, as for EDTA clearance, no effect was seen. The pattern of radiosensitivity observed in this study for .ft Ift ( ± 2 s.e.) for leg tumours was 2.03 (1.87-2.22) ( Table I) compared with 1.87 (1.60-2.23) and for flank tumours was 3.06 (2.36-4.34) (Table I ) compared with 3.57 (2.60-5.64) . The BW12C-induced increase in hypoxic fraction by a factor of 5.0 (2.3-11.3) for the leg tumour (Table I) is consistent with our previous observation of increases in survival by factors of 7.0 (5.0-9.0) assayed immediately and 3.8 (1.8-5.8) assayed 24 h after irradiation for this tumour grown in the leg following a radiation dose of 13 Gy (Honess et al., 1991b) . The increase in hypoxic fraction observed in the flank, a factor of 5.9 (1.9-18.2) ( Table I ) was very similar to that seen in the leg, although since the initial hypoxic fraction was substantially higher, the ultimate effect was to bring the degree of hypoxia much closer to the anoxic state than was the case for the leg tumour.
In the KHT tumour, BW12C increased the hypoxic fraction in subcutaneous tumours from 16 (15-18)% to 69 (62-77)%, i.e. by a factor of 4.2 (3.7-4.9). This effect is comparable with that reported for KHT (Adams et al., 1989) and Lewis lung where BW12C increased the hypoxic fraction from around 10% to 'close to' 100%. In KHT intramuscular leg tumours we found that the increase in hypoxic fraction was by a factor of 3.8 (2.8-5.3), again very simliar to that in flanks, but this was inadequate to bring to the level of hypoxia close to anoxic levels because the initial hypoxic fraction was low. The hypoxic fraction for the KHT tumour in the leg, 0.96 (0.80-1.14)% (Table I) , was notably lower than the 10% to 30% reported by other laboratories (Siemann et al., 1978; Siemann & Macler, 1986; Siemann & Keng, 1987) , but it has been shown to increase from 10% for 300-400 mg tumours to nearly 40% for 600-700 mg tumours (Hill, 1980) . In the present study, tumour size was particularly carefully controlled in these experiments, using only tumours between 8.5 and 9.0 mm mean diameter. It therefore seems likely that this rather low hypoxic fraction observed in small intramuscular tumours is attributable to the size of the tumours used, rather than to differences in the tumour as used in different laboratories, although the latter cannot be ruled out. The main conclusion from the radiosensitivity studies was therefore that the increase in hypoxic fraction was very similar, irrespective of the type of tumours or its initial hypoxic fraction.
Prolonged hypoxia and/or reduced pH thermosensitise cells in vitro (Hahn, 1974; Gerweck et al., 1979; Overgaard & Bichel, 1977; Overgaard & Neilsen, 1980) ; however since hypoxia typically results in decreased pH, it can be difficult to determine the relative contributions of these interdependent factors to the ultimate toxic effect, particularly in vivo. Acute hypoxia induced by inhibition of blood flow has also been shown to potentiate thermal damage in two mouse tumours (Horsman et al., 1989 , Honess et al., 1991a . These observations form the rationale for testing BW12C as a potentiator of thermal killing in vivo. We have previously demonstrated that the drug does not thermosensitise cells in vitro (Honess, unpublished observations) and have also shown that BW12C does not thermosensitise the RIF-1 tumour in the leg (Honess et al., 1989) . However in this tumour the hypoxic fraction is only increased to 1.5% by BW12C (Table I) . Clearly a tumour with a higher hypoxic fraction would be better system in which to test the hypothesis that BW12C may thermosensitise tumours, and the KHT tumour was selected on the basis of published data on its hypoxic fraction (see above). Leg tumour size was very carefully controlled within the same limits for both the thermosensitivity and radiosensitivity experiments, and these limits were determined by the requirements of the hyperthermia system in order to ensure uniformity of temperature. The radiosensitivity data showed that the hypoxic fraction of the KHT leg tumours was increased to around 4% by BW12C, which was significantly higher than the hypoxic fraction of 1.5% for BW12C-treated RIF-1 in the leg, but far from full radiobiological hypoxia. The data presented in the Results section show that BW12C did not increase the thermal damage produced by heat at temperatures from 43°C to 44°C. The small but measurable growth delay caused by BW12C alone is at first sight in contrast to the absence of cell killing by this dose of drug seen in the cell survival studies. However, the drug did cause marked reduction in blood flow (Figure 2 ) and hence deprivation of nutrition for a period sufficient to check the growth of this rapidly growing tumour. In studies with hydralazine, using this tumour system in this site, we have previously shown that growth delay is closely related to duration of inhibition of blood flow in addition to its dependence on cell killing (Honess et al., 1991a) . We conclude from the present data that the degree of hypoxia induced by BW12C was inadequate to alter the thermal response of the tumour. We were unable to investigate the effect of heat on the tumour in the flank as the hyperthermia system is designed only for the treatment of leg tumours.
The comparative data on the effects of BW12C on relative perfusion of RIF-1 tumours grown in the leg and flank (Figure 2 ) confirm the preliminary report (Honess et al., 1989 ) that perfusion is reduced. The data strongly suggest that the reduction in perfusion contributes to the increase in hypoxic fraction demonstrated to Figure 1 and Table I . The time-course of the perfusion effects is such that perfusion approaches its nadir during irradiation, which starts 30 min after drug administration and continues for e.g. approximately 30min for 20Gy. We have previously shown that maximum radioprotection of the RIF-1 tumour occurs when radiation is started around 30min after BW12C administration, whereas the maximum haemoglobin modification is observed 5 min after giving BW12C and this modification decays with a half-life of about 1.25 h (Honess et al., 1991b) .
The development of radioprotection therefore appears to correlate rather better with the time-course of the perfusion changes than with the haemoglobin modification. The data are consistent with radioprotective hypoxia initially (5 min after giving the drug) being primarily due to altered blood chemistry, then as the haemoglobin alteration decays (1 h after the drug) the effect of blood flow reduction becomes relatively more important in maintaining hypoxia. By 2 h after the drug, when blood flow has normalised and only 25% of the blood is modified, all radioprotection is lost.
The present data show that the reduction in perfusion in the leg tumours appears to be secondary to a reduction in perfusion of the muscle, the tissue 'feeding' the tumour, while for the intradermal flank tumours the reduction is not dependent on the perfusion of the skin. The reduction in muscle perfusion was not significant in the preliminary experiments (Honess et al., 1989) , where absolute values for per cent injected activity per gram were pooled rather than per cent of mean control values and where there was greater variation in the reproducibility of control values than in the present series of experiments; this probably obscured the changes in muscle. The reason for the difference in response between intramuscular and intradermal tumours and their respective upstream tissues is not clear. However, the proportional changes in perfusion are broadly similar in both sites, with a larger reduction in the flank tumours. This is consistent with the larger increase in hypoxic fraction measured for flank than for leg tumours (Table I) although there is no evidence for a significant difference between the increases in flank and leg.
The time course for change in relative perfusion after BW12C in the remaining normal tissues measured was somewhat similar in that a peak at either 30 min or 1 h was followed by a drop at 2 h. However, in kidney, spleen and lung this peak represented an increase in relative perfusion followed by return to normal values, whereas in liver the peak did not form a significant increase, but the subsequent fall constituted a significant decrease from control values (Figure 2 ). The rises observed may either reflect actual increases in absolute blood flow, or possibly may indicate a decrease in cardiac output at around 1 h. Relative tissue perfusion is a measure of absolute blood flow as a proportion of cardiac output. Hence RTP must inevitably rise when cardiac output falls but absolute blood flow remains BW12C: HYPOXIA AND BLOOD FLOW 721 unchanged. Similarly a reduction in cardiac output by the same proportion as a reduction in blood flow will cause no change in RTP, but a reduction in blood flow by a greater proportion than a reduction in cardiac output will be measured as a decrease in RTP. The similarity of pattern of RTP changes in kidney, spleen, lung and liver suggested that the changes in RTP might be due to a drop in cardiac output with a nadir at 1 h after BW12C and recovery commencing by 2 h. It is not currently feasible to measure cardiac output in unanaesthetised mice, so a direct measurement was not possible. Functional assays of the effects of BW12C on these four organs were considered, and we chose to examine the effects of BW12C on renal clearance. The data presented in Table II shows that 30 min after BW12C, the time at which RTP was maximal, there was no effect on EDTA or 125i-iodohippurate clearance, while immediately after giving the drug there was a very small decrease in EDTA clearance rate, by a factor ( ± 2 s.e.) of 1.26 ± 0.27. EDTA clearance is used as an assay for glomerular filtration rate and iodohippurate clearance as an assay for effective renal plasma flow (Sweny et al., 1989) . These experiments showed that kidney function was hardly altered by BW12C, and a possible inference is that the RTP measurements may not indicate an increase in absolute kidney flow but a decrease in cardiac output. The RTP data are compatible with this hypothesis, but there is no clear evidence to support it. Nonetheless, if it is true, since any change in cardiac output is a constant in the determination of RTP in all tissues measured, the absolute reductions in flow in tissues where RTP dropped must have been larger than the measured reductions in RTP i.e. the reductions in tumour RTP would be underestimates of the changes in absolute tumour blood flow.
In summary, BW12C induces a comparable increase in hypoxic fraction in both the RIF-I and KHT tumours, whether these tumours are grown intramuscularly in the leg (with a low hypoxic fraction) or intradermally or subcutaneously in the flank (with a hypoxic fraction 15 to 17-fold higher). The blood flow studies indicate that a reduction in tumour perfusion is likely to be an important factor in this increase in hypoxic fraction. It is not clear from these studies how much of the radioprotection is attributable to the reduction in perfusion and how much is due to changes in oxygen release by alteration of blood chemistry by BW12C.
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